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Domain interactions of the human androgen receptor
(AR) dimer were investigated using a protein-protein
interaction assay in which the NH2- and carboxyl-termi-
nal regions of human AR were fused to the Saccharomy-
ces cerevisiae GAL4 DNA-binding domain and herpes
simplex virus VP16 transactivation domain to produce
chimeric proteins. Transcriptional activation of a GAL4
luciferase reporter vector up to 100-fold was greater
than Fos/Jun leucine zipper binding, indicating stable
AR interaction between AR NH2-terminal residues 1–503
and steroid-binding domain residues 624–919 that was
specific for and dependent on androgen binding to the
steroid-binding domain and was inhibited by anti-an-
drogen binding. Deletion mutagenesis within the NH2-
terminal region indicated transactivation domain resi-
dues 142–337 were not required for dimerization,
whereas deletions near the NH2 terminus (D14–150) or
NH2-terminal to the DNA-binding domain (D339–499) re-
duced or eliminated the AR interaction, respectively. An
NH2-/NH2-terminal interaction was also observed, but
no interaction was detected between ligand-free or
bound steroid-binding domains. The results indicate
that high affinity androgen binding promotes interac-
tions between the NH2-terminal and steroid-binding do-
mains of human AR, raising the possibility of an andro-
gen-induced anti-parallel AR dimer.
The androgen receptor (AR)1 is a ligand-activated transcrip-
tion factor that requires high affinity androgen binding to
initiate a series of molecular events leading to specific gene
activation required for male sex development. In its unliganded
state, AR resides in the cytoplasm (1), where it rapidly de-
grades (2) and is regulated by a cytoplasmic dnaJ homologue
(3). High affinity androgen binding slows AR degradation in a
concentration-dependent manner, accounting at least in part
for the physiological differences between the biologically active
androgens (4). Androgen binding activates a bipartite nuclear
targeting signal (5) and triggers receptor dimerization and
acquisition of DNA binding that involves distal regions of the
AR (6). Once activated, AR binds androgen response elements
that resemble the simple consensus glucocorticoid response
element (7) or more distinct, specific complex response ele-
ments (8–10). Little is known, however, about transcription
factors that interact with AR during gene activation or the role
of AR phosphorylation (11). That AR is crucial for specific gene
regulation required for male sex development is demonstrated
by an abundance of AR gene mutations that result in different
degrees of impaired male sex development characteristic of the
androgen insensitivity syndrome (12–15).
Steroid receptor dimerization is well documented (16–19)
and apparently does not have a strict requirement for ligand or
DNA binding, particularly with the estrogen (ER) (20–24) and
progesterone receptors (25, 26). The glucocorticoid receptor
forms ligand-dependent homodimers independent of DNA
binding (27). A mutant progesterone receptor lacking the ste-
roid-binding domain fails to dimerize in solution but activates
a reporter gene, suggesting that receptor dimerization medi-
ated through the steroid-binding domain is not a requirement
for DNA binding and that dimerization after DNA binding is
mediated by the DNA-binding domain (28). Direct evidence for
receptor dimerization was revealed in electron micrographs
showing dumbbell shaped glucocorticoid receptor monomers
with globular NH2-terminal and steroid-binding domains and
four-leaf clover shaped dimers. It was not established, however,
whether dimer orientation was parallel or anti-parallel (29).
Additional protein-protein interactions and alterations in DNA
structure are indicated by increased gene activation following
cooperative dimer binding to tandem hormone response ele-
ments (30). ER dimerization involves hydrophobic interactions
between the steroid-binding domains (31) and, for thyroid hor-
mone receptor a, regions outside the steroid-binding domain
(32). In addition, a leucine zipper-like structure in the thyroid
receptor ligand-binding domain mediates heterodimerization
with the retinoic acid receptor (33).
Numerous recent studies have taken advantage of a protein-
protein interaction assay developed originally in yeast (34) and
later adapted for mammalian cells (35) that relies on the coex-
pression of two fusion proteins, each containing a protein or
protein region coupled to a transcription factor functional do-
main. Stable protein-protein interactions bring together DNA
binding and transactivation functions that regulate a reporter
gene. Using this assay, we demonstrate an androgen-depend-
ent interaction between the AR NH2- and carboxyl-terminal
domains that raises the possibility of an anti-parallel oriented
AR dimer.
EXPERIMENTAL PROCEDURES
Materials—The following reagents were purchased. Monkey kidney
COS-1 and Chinese hamster ovary (CHO) cells were from the American
Type Culture Collection (Rockville, MD); a minimum essential medium
and prestained protein molecular weight standards were from Life
Technologies, Inc.; Dulbecco’s modified essential medium with high
glucose with or without phenol red was from JRH Biosciences; fetal calf
serum was from Hyclone Laboratories (Logan, UT), and bovine calf
* This work was supported by Grants HD16910 and P30-HD18968
from the National Institute of Child Health and Human Development
Center for Population Research. The costs of publication of this article
were defrayed in part by the payment of page charges. This article must
therefore be hereby marked “advertisement” in accordance with 18
U.S.C. Section 1734 solely to indicate this fact.
i To whom correspondence should be addressed: Laboratories for
Reproductive Biology, CB#7500, Rm. 374, Medical Sciences Research
Bldg., University of North Carolina, Chapel Hill, NC 27599. Tel.: 919-
966-5159; Fax: 919-966-2203.
1 The abbreviations used are: AR, androgen receptor; ER, estrogen
receptor; CHO cells, Chinese hamster ovary cells; PCR, polymerase
chain reaction; DHT, dihydrotestosterone; R1881, methyltrienolone;
hydroxyflutamide, a,a,a-trifluoro-2-methyl-49-nitro-m-lactotoluidide.
THE JOURNAL OF BIOLOGICAL CHEMISTRY Vol. 270, No. 50, Issue of December 15, pp. 29983–29990, 1995
© 1995 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in U.S.A.
29983
This is an Open Access article under the CC BY license.
serum was from Irvine Scientific (Santa Ana, CA); AR PG-21 rabbit
polyclonal AR anti-peptide antiserum was from Affinity Bioreagents,
Inc. (Neshanic Station, NJ); [3H]methyltrienolone [17a-methyl-
3H]R1881, 80 Ci/mmol was from DuPont NEN; hydroxyflutamide was
provided by R. O. Neri (Schering Corporation, Bloomfield, NJ); deep
vent polymerase, T4 DNA ligase, and restriction enzymes were from
New England Biolabs (Beverley, MA); Sequenase was from U. S. Bio-
chemical Corp.; diethylaminoethyl dextran was from Pharmacia Bio-
tech Inc.; D-luciferin was from Analytical Luminescence; cell lysis buffer
was from Ligand Pharmaceuticals (San Diego, CA); phenylmethylsul-
fonyl fluoride and general chemicals were from Sigma; ECL Western
blotting detection kit was from Amersham Corp.; and Immobilon-P was
from Millipore (Bedford, MA).
Expression Plasmids—Eukaryotic expression vectors pGALO con-
taining the DNA-binding domain of the Saccharomyces cerevisiae GAL4
protein (amino acid residues 1–147) and pNLVP coding for the tran-
scriptional activation domain of the herpes simplex virus VP16 protein
(residues 411–456) were previously described (36) and kindly provided
by Gordon Tomaselli, Johns Hopkins University. Expression vectors
contain the SV40 promoter, nuclear targeting signals, and a 39 multiple
cloning site. Control plasmid pGAL-Fos contains the Fos leucine zipper
region (amino acid residues 137–216) and pVP-Jun, the Jun leucine
zipper region (residues 250–334) as described previously (36) and
kindly provided by Gordon Tomaselli and Chi V. Dang, Johns Hopkins
University. Full-length human AR was cloned in frame in both vectors
using polymerase chain reaction (PCR) mutagenesis to place an NdeI
site at the initiation codon. A triple ligation reaction was performed
with the NdeI/AflII NH2-terminal AR PCR fragment, the AflII/XbaI
carboxyl-terminal AR fragment from pCMVhAR (1), and the NdeI/XbaI
fragments of the pGALO or pNLVP expression vectors. pGAL-A1 (A1
comprising human AR amino acids 1–503) and pVP-A1 were con-
structed by deleting sequence coding for carboxyl-terminal residues
504–919 using KpnI/XbaI followed by ligation of the filled ends. NH2-
terminal deletion and insertion mutants pCMVhARD14–150,
pCMVhARD142–337, pCMVhARD339–499, and pCMVhARGln66 pre-
viously described (4) were used to clone the corresponding deletions into
the pGAL-A1 and pVP-A1 vectors or into the full-length pGAL-hAR and
pNLVP-hAR vectors using unique sites in the AR coding sequence to
exchange the deletion fragment or, in the case of the D14–150 deletion,
using PCR to include the NdeI site at the initiation codon. pGALD-H
(human AR amino acids 624–919; 624–627 from exon C, 628–919
exons D–H) was constructed using PCR to create an NdeI site at
methionine 624 and was cloned into the NdeI/XbaI sites in the
polylinker of pGALO. pGAL-LNCaPD-H was constructed in the same
manner using pCMV-LNCaP AR (37) as template for PCR. Plasmids
were amplified using DH5a E. coli cells and DNA isolated by banding in
CsCl. Fusion genes created using PCR were sequenced using Sequenase
to verify the absence of random mutations.
Cell Culture and Transient Transfections—CHO cells were main-
tained in a minimum essential medium containing 10% fetal calf se-
rum, 20 mM Hepes, pH 7.2, and penicillin and streptomycin. CHO cells
at 50% confluence were transiently transfected with expression and
reporter plasmids using DEAE-dextran as described previously (38).
Unless otherwise stated for the protein-protein interaction assay 1 mg
each of the GAL4 and VP16 fusion protein plasmids and 5 mg of reporter
plasmid G5E1bLuc (provided by Gordon Tomaselli) were cotransfected
into CHO cells (0.4 3 106 cells/60-mm dish). The reporter vector had
five tandem copies of the GAL4-binding sites, the E1bTATA promoter
as described previously (39), and the luciferase coding sequence. Imme-
diately after transfection, cells were placed in 0.2% serum-containing
medium and 24 h later into serum-free, phenol red-free medium in the
presence or the absence of steroid. Medium with or without hormone
was replaced 3 h prior to harvest. Plates were washed with phosphate-
buffered saline, harvested in 0.5 ml of cell lysis buffer, and frozen at
280 °C until assayed for luciferase activity. Lysates were supplemented
with 8 mM MgCl2, 1 mM dithiothreitol, and 0.4 mM phenylmethylsulfo-
nyl fluoride. Relative light units were determined using a monolight
2010 Analytical Luminescence Laboratory luminometer after combin-
ing 0.4 ml of reaction buffer (15 mMMgCl2, 5 mM ATP, 0.5 mg/ml bovine
serum albumin, and 15 mM glycylglycine, pH 7.8), 0.1 ml of cell lysate,
and 0.1 ml of 1 mM D-luciferin injected automatically. All experiments
were performed in duplicate and repeated at least three times.
Immunoblots and Binding Assays—Expression of GAL4- and
VP16-AR fusion proteins was assessed on immunoblots and by whole
cell steroid binding assays. Monkey kidney COS-1 cells were grown in
Dulbecco’s modified essential medium supplemented with 4.5 g/liter
glucose and L-glutamine, 10% fetal calf serum, 20 mM Hepes, pH 7.2,
and antibiotics. For immunoblot analysis, COS cells plated in 60-mm
dishes (0.45 3 106 cells/dish) were transiently transfected with 5 mg of
wild-type or mutant AR chimeric expression plasmids using DEAE-
dextran (38). Cells were maintained in Dulbecco’s modified essential
medium with 4.5 g/liter glucose and L-glutamine with 10% bovine calf
serum and, for cells transfected with plasmids expressing the AR ste-
roid-binding domain, supplemented with 0.1 mM dihydrotestosterone.
48 h after transfection, cells were washed in phosphate-buffered saline
and harvested in 0.1 ml of 2% SDS, 10% glycerol, and 10 mM Tris, pH
6.8. b-Mercaptoethanol (4%) and bromphenol blue (1%) were added, and
the samples were boiled for 5 min. 20-ml aliquots were analyzed in SDS
containing 8% acrylamide gels as described previously using AR anti-
peptide rabbit antiserum AR32 (40) or AR PG-21 (41) and the ECL
immunoblotting detection kit.
Androgen binding was determined in COS and CHO cells using a
whole cell binding assay (38) for vectors comprised of exons D–H (res-
idues 624–919) (42). COS cells in 12-well (105 cells/well) or 35-mm (0.25
3 106 cells/plate for Scatchard plot analysis) tissue culture plates were
transiently transfected using DEAE-dextran with 1 mg of GAL4 or VP16
fusion plasmids containing wild-type or LNCaP AR steroid-binding
domain. Cells were maintained for 48 h in Dulbecco’s modified essential
medium with 4.5 g/liter glucose and L-glutamine media containing 10%
bovine calf serum and labeled for 2 h at 37 °C with 5 nM [3H]R1881 in
serum-free, phenol red-free medium in duplicate. For Scatchard anal-
ysis, cells were incubated with 0.05–4 nM [3H]R1881 in the presence
and the absence of a 100-fold excess of unlabeled R1881 for 2 h at 37 °C.
Aliquots of free [3H]R1881 were taken, and the cells were washed in
phosphate-buffered saline and collected in SDS sample buffer for scin-
tillation counting. Nonspecific binding was determined by parallel in-
cubations in the presence of a 100-fold excess unlabeled R1881. Label-
ing medium was removed, and cells were washed twice with phosphate-
buffered saline and harvested in 0.2 ml of 2% SDS, 10% glycerol, and 10
mM Tris, pH 6.8. Radioactivity was determined by scintillation
counting.
RESULTS
Expression of GAL4-AR and VP16-AR Fusion Proteins—In-
termolecular interactions within the AR dimer were investi-
gated using a protein-protein interaction assay in mammalian
cells. Fusion protein expression vectors contained partial AR
sequence cloned in frame and carboxyl-terminal to the S. cer-
evisiae GAL4 DNA-binding domain or the herpes simplex virus
VP16 protein transactivation domain (shown schematically in
Fig. 1). Activation of the GAL4-luciferase reporter vector re-
sults when regions of AR interact stably after expression of the
chimeras in CHO cells. GAL-Fos and VP-Jun vectors express-
ing Fos and Jun leucine zipper fusion proteins (36) were used
as a positive control.
GALD-H and VPD-H comprise the GAL4 DNA-binding and
VP16 transactivation domains, respectively, fused NH2-termi-
nal to AR steroid-binding domain residues 624–919. Epitopes
for AR antibodies were not present in this region, so these
fusion proteins were quantitated by ligand binding after ex-
pression in CHO and COS cells. GALD-H and VPD-H displayed
high affinity (Kd 5 0.11 6 0.02 nM) saturable binding of the
synthetic androgen [3H]R1881. Equilibrium binding affinity
FIG. 1. Schematic representation of GALD-H and VP-A1 chi-
meric vectors. AR exons D–H coding for residues 624–919 were in-
serted 39 into pGALO containing GAL4 protein DNA-binding domain
amino acid residues 1–147. AR DNA sequence coding for residues 1–503
was cloned into pNLVP 39 of the herpes simplex virus VP16 protein
transcriptional activation sequence coding for residues 411–456. Re-
porter vector G5E1bLuc has five GAL4-binding sites, the E1b promoter,
and the luciferase coding sequence.
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was indistinguishable from full-length wild-type AR; however,
these fragments would be expected to have increased ligand
dissociation rates based on results with AR deletion mutants
lacking the NH2-terminal domain (4). Expression levels were
similar for the two constructs and were approximately 10-fold
greater in COS cells than in CHO cells (data not shown).
GAL-A1 and VP-A1 comprise the GAL4 DNA-binding and
VP16 transactivation domains, respectively, fused NH2-termi-
nal to AR NH2-terminal residues 1–503 (A1), and express at
similar levels as 90–95-kDa proteins on immunoblots using an
AR anti-peptide antibody, shown for VP-A1 in Fig. 2 (lane 1).
Deletions within the NH2-terminal region resulted in corre-
spondingly smaller proteins expressed either in CHO and COS
cells (Fig. 2, lanes 2–4), whereas expansion of the glutamine
repeat from 21 to 66 residues resulted in a slightly larger
peptide (Fig. 2B, lane 5). All were smaller than the 120-kDa
full-length, wild-type AR (Fig. 2, lane 6).
Androgen-dependent Interaction between the AR Steroid-
binding and NH2-terminal Domains—In the absence of andro-
gen, luciferase activity was negligible when cotransfecting
GALD-H with VP-A1 (Fig. 3). Treatment with 1 nM DHT-
induced luciferase activity greater than that observed with the
Fos/Jun leucine zipper chimeras relative to background activ-
ity (Fig. 3). Similar results were obtained using COS cells for
transfection (data not shown); however, CHO cells were used in
subsequent experiments due to lower background activity. No
significant transactivation was observed in CHO cells in the
presence of androgen when either plasmid was transfected
with the other parent plasmid lacking AR sequence (Fig. 3).
The results indicate an androgen-dependent stable interaction
between the AR steroid-binding domain and the NH2-terminal
region.
Only a 2-fold induction of luciferase activity was observed
using the reciprocal chimeras GAL-A1 and VPD-H (Fig. 3),
suggesting a preferential orientation for fusion protein inter-
action. GAL-A1 alone activated luciferase expression (Fig. 3)
presumably resulting from linking the AR transactivation do-
main to the GAL-4 DNA-binding domain, thus increasing back-
ground activity in the NH2-/carboxyl-terminal interaction us-
ing this construct. Cotransfecting GALD-H and VPD-H both
containing the AR steroid-binding domain failed to activate the
reporter vector in the presence or absence of androgen (Fig. 3).
Transfecting GAL-A1 with VP-A1 increased activation 4–5-fold
over the activity of GAL-A1 alone (Fig. 3), indicating a ligand-
independent interaction between the AR NH2-terminal do-
mains. The high transcriptional activity induced by GAL-A1
with VP-A1 was likely due in part to the presence of three
transactivation domains, two from the AR NH2-terminal do-
mains and one from VP-16. The lower fold induction by the
NH2-/NH2-terminal interaction may therefore reflect a weaker
interaction than that observed for the androgen-induced NH2-
/carboxyl-terminal interaction (4–5- versus 59-fold; Fig. 3).
Steroid Specificity and Concentration Dependence—Steroid
specificity of the GALD-H and VP-A1 interaction was investi-
gated by determining transcriptional activation in the presence
of androgens, the antiandrogens hydroxyflutamide and cypro-
terone acetate, and other steroids. The strongest transcrip-
tional activation was observed at 1 nM DHT and between 1 (Fig.
4) and 10 nM R1881 or testosterone. Hydroxyflutamide up to 1
mM failed to activate luciferase activity (Fig. 4).
Because hydroxyflutamide is a potent antiandrogen, we in-
vestigated whether it would disrupt the NH2-/carboxyl-termi-
nal interaction in the presence of androgen. Increasing concen-
trations of hydroxyflutamide between 0.2–1 mM inhibited
androgen-induced gene activation (Fig. 4). Estradiol, progester-
one, and cyproterone acetate failed to induce luciferase activity
and at 0.5 mM inhibited transcriptional activation induced by 1
nM DHT (Fig. 5). The results indicate that the NH2-/carboxyl-
terminal interaction induced by androgens is blocked by mod-
erate affinity ligands such as hydroxyflutamide, progesterone,
and estradiol, paralleling the activation and inhibition proper-
ties of these ligands with wild-type, full-length AR.
Activity of the LNCaP AR Mutant—It was shown previously
that the mutant AR in the androgen-dependent human pros-
tate cancer cell line, LNCaP, contains a single base mutation in
the steroid-binding domain that changes threonine 877 to ala-
nine that results in increased affinity for hydroxyflutamide
with concomitantly increased agonist activity (43–45). We in-
serted the LNCaP Thr-877 3 Ala mutation into GALD-H and
tested for the NH2-terminal/steroid-binding domain interac-
tion. Whole cell binding assays using [3H]R1881 showed simi-
lar binding affinities for GALD-H and GAL-LNCaPD-H (data
not shown). In the presence of 1 nM DHT, greater than 100-fold
induction of luciferase activity indicated an NH2-/carboxyl-ter-
minal interaction similar to wild-type AR (Fig. 4). At 1 mM,
hydroxyflutamide-induced luciferase activity almost 10-fold
and was a less active inhibitor of androgen-induced complex
formation, with luciferase activity remaining approximately
10-fold (Fig. 4). This result is in agreement with the known
agonist activity of hydroxyflutamide acquired by the LNCaP
mutation (43–45). Estradiol and progesterone similarly in-
duced luciferase activity by GAL-LNCaPD-H and VP-A1,
whereas no detectable activity was observed with these ste-
roids with the wild-type GALD-H and VP-A1 chimeras (Fig. 5).
Cyproterone acetate did not induce luciferase activity of the
wild-type or LNCaP mutant chimeras. All three ligands, estra-
diol, progesterone, and cyproterone acetate, at 0.5 mM were less
FIG. 2. Immunoblots of wild-type and deletion mutant VP-A1
chimeras expressed in CHO and COS cells. Immunoblots were
performed as described under “Experimental Procedures” where the
VP-A1 expression vectors (5 mg) were transfected into CHO (A) or COS
(B) cells. The blot was probed with antibodies AR32 (40) and AR PG-21
(41) raised against AR NH2-terminal peptides. Molecular mass stand-
ards were analyzed in parallel for gel calibration. Shown are VP-A1
(lane 1), VP-A1D14–150 (lane 2), VP-A1D142–337 (lane 3), VP-
A1D339–499 (lane 4), VP-A1Gln66 (B, lane 5), pCMVhAR wild-type
human AR expression vector (lane 6), and the parent pCMV5 vector
lacking AR sequence (lane 7).
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active inhibitors of DHT-induced luciferase activity of GAL-
LNCaPD-H and VP-A1 relative to wild-type GALD-H and
VP-A1 chimeras (Fig. 5). Thus, although the magnitude of the
interaction was 5–10-fold less than that observed with DHT,
the NH2-/carboxyl-terminal interaction induced by hydroxyflu-
tamide, estradiol, and progesterone with the threonine 877 to
alanine mutation correlated with the agonist activities of these
ligands with the full-length LNCaP mutant AR.
NH2-terminal Deletions Define the Dimerization Do-
main—To characterize the dimerization region within the AR
NH2-terminal domain, PCR mutagenesis was used to create
deletions within VP-A1 (shown schematically in Figs. 6 and 7)
for cotransfection with GALD-H, GAL-LNCaPD-H, and GAL-
A1. Expression levels of the deletion mutants were similar as
determined by immunoblotting (see Fig. 2). Deletion of the AR
transactivation region (VP-A1D142–337) resulted in 14-fold
stimulation of luciferase activity (Fig. 6), representing a signif-
icant decrease relative to the wild-type sequence. Because the
AR transactivation domain likely contributes to luciferase in-
duction, it is possible that the decrease reflects deletion of the
AR activating region rather than a decrease in dimerization.
Deletion immediately NH2-terminal to the DNA-binding do-
main (VP-A1D339–499) abolished luciferase activity (Fig. 6)
even after a 5-fold increase in plasmid concentration (data not
shown). Deletion near the NH2 terminus (VP-A1D14–150) also
inhibited transcriptional activation, with 2–5-fold induction of
luciferase activity using a 5-fold higher plasmid DNA concen-
tration (Fig. 6). Expansion of the NH2-terminal polymorphic
glutamine repeat from 21 (residues 58–78 in wild-type AR) to
66 glutamine residues (VP-A1Gln66) had little effect on tran-
scriptional activation of luciferase (Fig. 6). Expansion of the
glutamine repeat is associated with spinal/bulbar muscular
atrophy (Kennedy’s disease) (46), and thus, the amplified re-
peat does not interfere with this aspect of AR dimerization, in
agreement with its wild-type level of activation.2 Results using
the NH2-terminal deletion and insertion mutants with the
GAL-LNCaPD-H mutant were essentially identical to those
with wild-type GALD-H fusion protein (data not shown).
The NH2-/NH2-terminal interaction was investigated using
the VP-A1 deletion mutants described above. Inhibition was
observed after deleting transactivation domain residues 142–
337 and to a lower extent by deletion of residues 339–499 or
14–150 (Fig. 7). Expanding the glutamine repeat to 66 residues
as described above slightly enhanced the interaction. Thus,
different regions appear to be involved in the NH2-/NH2-termi-
nal interaction than in NH2-terminal interaction with the an-
drogen-bound steroid-binding domain.
Smaller Domains within the Interacting Regions—Insertion
of shorter regions of AR coding sequence into GAL4 and VP16,
such as NH2-terminal fragments 1–150 or 339–503 linked to
VP16, failed to activate the reporter plasmid when cotrans-
fected with GALD-H and analyzed in the presence of androgen
(data not shown). Similarly, subdividing the steroid-binding
domain into regions encoded by exons D–E (residues 624–780)
and F–H (residues 774–919) resulted in no reporter vector
2 E. M. Wilson, unpublished data.
FIG. 3. Luciferase activity induced by the chimeric vectors. Combinations of the indicated parent and chimeric expression vectors (1 mg
DNA/0.45 3 106 CHO cells) were cotransfected into CHO cells together with 5 mg of G5E1bLuc reporter vector. Luciferase activity is expressed as
optical units, where fold induction reflects the ratio of activity determined in the presence and the absence of 1 nM DHT or the ratio of activity of
the interacting vectors over the GAL chimera alone. GAL-Fos and VP-Jun containing the leucine zipper regions as described under “Experimental
Procedures” served as a positive control.
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activation. The results suggest that the sites of interaction
localize to larger domains that may involve concerted actions
within the NH2-terminal and entire steroid-binding domains,
with the latter required for androgen binding.
DISCUSSION
The objective of the present study was to establish whether a
direct interaction occurs between the NH2-terminal and ste-
roid-binding domains in androgen-induced AR dimer forma-
tion. Domain interactions were analyzed by reporter gene ac-
tivation using fusion proteins that linked the NH2- and
carboxyl-terminal regions of human AR to the GAL4 DNA-
binding or VP16 transactivation domains. The results support
previous evidence that in vivo dimerization of human AR is
mediated through direct intermolecular interactions between
the androgen-bound steroid-binding domain and the NH2-ter-
minal region. The dependence on androgen binding and inhi-
bition by an antiandrogen and other steroids parallels proper-
ties of native AR and raises the possibility of an androgen-
activated, anti-parallel AR dimer.
Although the present data do not rule out that the ligand-
induced NH2-/carboxyl-terminal interaction occurs intramo-
lecularly, previous studies using baculovirus-expressed AR
fragments support a ligand-induced intermolecular interac-
tion. Androgen-dependent dimerization was observed between
NH2-terminal plus DNA-binding domain and DNA plus ste-
roid-binding domain fragments (6). However, as the DNA-bind-
ing domain is implicated in receptor dimerization through the
so-called D box region (47–49) with the other monomer (50, 51),
the DNA-binding domain could have accounted for the ob-
served AR dimerization. In the present study, the AR DNA-
binding domain, which itself dimerizes,3 was excluded from the
chimeric proteins, indicating an additional dimerization inter-
face between the NH2-terminal and androgen-bound steroid-
binding domain of AR. Further support for AR NH2- and car-
boxyl-terminal interactions comes from kinetic studies where
the dissociation rate of bound androgen slows about 5-fold by
the presence of the NH2-terminal domain despite no change in
equilibrium dissociation constant (4). Crystallographic data of
glucocorticoid receptor/DNA interactions (50) and the asym-
metric dimer proposed for the vitamin D receptor (53) suggest
a ligand-activated anti-parallel dimer may be the active con-
formation for other members of the steroid receptor family.
The two regions of the AR NH2-terminal domain required
most for carboxyl-terminal interaction were immediately NH2-
3 Marschke, K. B., Tan, J. A., Kupfer, S. R., Wilson, E. M., and
French, F. S. (1995) Endocrine 3, 819–825.
FIG. 4. Luciferase activity induced by wild-type and LNCaP mutant GALD-H and VP-A1 with different androgens and the
antiandrogen hydroxyflutamide. GALD-H or GAL-LNCaPD-H with VP-A1 (1 mg of plasmid DNA each) and the G5E1bLuc reporter vector (5
mg) were cotransfected into CHO cells and incubated with 1 nM DHT, R1881, testosterone (T), and/or increasing concentrations of hydroxyflutamide
(OHFL) as indicated. The GAL-LNCaPD-Hmutant contains a Thr-8773 Ala mutation in the steroid-binding domain. Fold induction, shown above
the error bars, was determined from the ratio of activity in the presence and absence of ligand. A representative of three experiments is shown.
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terminal to the DNA-binding domain and near the NH2 termi-
nus. Lack of a direct role of the more centrally positioned
transactivation domain might allow this region to remain ac-
cessible for transcription factor interaction. In our unpublished
studies and the work of others (54), deletion of the transacti-
vation domain creates a strong dominant negative AR inhibi-
tor, suggesting that loss of the transactivation domain does not
interfere with receptor dimerization. It is interesting, therefore
that this region or the region NH2-terminal to the DNA-binding
domain (residues 142–337 and 339–499, respectively) may be
involved in an interaction between the NH2-terminal domains
and may reflect an association that occurs in the unliganded
receptor that could contribute to suppression of activation in
the absence of ligand.
The affinity of the NH2-/carboxyl-terminal interaction ap-
pears to be similar to that observed for Fos-Jun leucine zipper
binding. When the Fos/Jun leucine zipper regions were fused to
progesterone receptor, agonist-induced progesterone receptor
dimerization persisted through the receptor dimerization do-
main, suggesting that ligand-induced receptor dimerization
was of equal or greater affinity than the Fos/Jun leucine zipper
interaction (55). Leucine zipper motifs are often involved in
transcription factor dimerization resulting in efficient DNA
binding (56). A heptad repeat of hydrophobic amino acid resi-
dues in the steroid-binding domain of mouse ER resembles a
leucine zipper, is conserved among the family of steroid recep-
tors, and is implicated in dimerization and high affinity estro-
gen binding (20). Like ER (57), other steroid receptors appear
to have two dimerization interfaces: a constitutive region in the
DNA-binding domain and a stronger, hormone-dependent re-
gion in the hormone-binding domain that may be involved in
stable dimer formation required for high affinity DNA binding.
The carboxyl-terminal end of the thyroid hormone receptor was
also implicated in receptor dimerization (58, 59).
Human AR and ER differ in the length of their NH2-terminal
domains, i.e. 559 amino acid residues in AR versus 185 in ER.
It is noteworthy, therefore, that a transcriptionally inactive AR
deletion mutant AR507–919, lacking all but 52 NH2-terminal
amino acid residues (4), dimerizes and binds DNA independent
of ligand binding (6) as observed with full-length ER (20–23)
but not full-length AR (6). The androgen-independent dimer-
ization of this AR deletion mutant suggests two forms of DNA-
binding homodimers: one for the AR deletion mutant AR507–
919 and perhaps ligand free ER and another for androgen-
bound full-length AR and perhaps ligand-bound ER. A parallel
dimer capable of binding DNAmay form constitutively through
interactions between the DNA-binding domains if no extended
NH2-terminal region interferes, in the case of ER and the AR
deletion mutant. However, the active configuration requiring
ligand binding for full-length AR might be anti-parallel and
depends on the presence of the NH2-terminal domain. This
hypothesis is supported by studies using glucocorticoid recep-
FIG. 5. Effects of estradiol, progesterone, and cyproterone acetate on the GALD-H and GAL-LNCaPD-H interaction with VP-A1.
VP-A1 and GALD-H containing wild-type or LNCaP mutant AR sequence were cotransfected into CHO cells with the reporter vector, G5E1bLuc,
as described under “Experimental Procedures” and incubated with 0.5 mM 17b-estradiol (E), progesterone (P), and cyproterone acetate (CA) in the
absence or the presence of 1 nM DHT as indicated. Shown are optical units and fold induction relative to the activity determined in the absence
of ligand. Shown is a representative of three independent experiments.
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tor deletion mutants, where deletion of the NH2-terminal do-
main changed the contact points within the dimer in cross-
linking studies and reduced the specificity of DNA binding (60).
Androgen-induced conformational effects on full-length AR
that might establish the anti-parallel dimer may be required
for DNA binding that results in transcriptional activation.
FIG. 6. Effect of AR NH2-terminal deletions on VP-A1 interaction with GALD-H. Several mutants with portions of the AR NH2-terminal
domain deleted, including VP-A1D14–150 (5 mg), VP-A1D142–337 (1 mg), VP-A1D339–499 (1 mg), VP-A1Gln66 (1 mg), or VP-A1 (1 mg), were
cotransfected with GALD-H (1 mg). The expanded glutamine repeat replaces 21 Gln residues with 66 Gln residues identified in a patient with
spinal/bulbar muscular atrophy (52). Relative luciferase activities are shown for GALD-H cotransfected in CHO cells with wild-type and deletion
mutants of VP-A1 in the absence and presence of 1 nM DHT. Amino acid residues deleted from AR are indicated by D. Shown are optical units and
fold induction relative to activity in the absence of DHT. GAL-Fos cotransfected with VP-Jun was a positive control and the parent vector VP16
lacking AR sequence cotransfected with GALD-H served as negative controls. The data shown are representative of three independent
experiments.
FIG. 7. Effect of ARNH2-terminal deletions on the VP-A1/GAL-A1 interaction. The VP-A1 mutant vector DNAs described in legend to Fig.
6 were cotransfected with GAL-A1, and luciferase activity was determined as described in the legend to Fig. 6. The data shown are representative
of three experiments.
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